Instadose Pharma Corp.


On November 23, 2021, the U.S. Securities and Exchange Commission (SEC) announced a temporary suspension in the trading of Instadose Pharma Corp. securities due to concerns regarding the adequacy and accuracy of information about the company in the marketplace. The SEC specifically noted stock price and volume increases of Instadose stock unsupported by the company’s assets and financial information, trading that may be associated with individuals related to a control person at the company, and operations at the company’s Canadian affiliate.  

Shares of Instadose Pharma stock fell more than 13% in intraday trading on November 23, 2021.

Lead Plaintiff deadline
class period
Case Documents
No documents available. Contact us if you need a case document.